Published in the journal, Lancet Neurology, a new study suggests that understanding stroke severity, as well as time to treatment, is key to delivering effective and safe thrombolysis treatment.
This study will compare tenecteplase, a newer clot-busting drug, with alteplase, which is currently the routine treatment used in hospitals.
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2) - TSA BHF 2015/01
Reducing blood pressure to prevent bleeding complications and improve outcome following clot-busting treatment for ischaemic stroke
Exploring the effects of lowering blood pressure and a lower dose of clot busting drug on stroke outcome
PRESS RELEASE - Issued by University of Leicester Press Office on Tuesday 10 May
University of Leicester involved in the international ENCHANTED trial to improve survival rates of stroke victims. Stroke Association funds UK arm of the trial.
A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
MR CLEAN is a Dutch trial that investigated treatment of a severe form of ischaemic stroke (blockage type stroke) with thrombolysis alone (dissolving a clot with clot-busting drugs), versus treatment with both thrombolysis.
Promising research results for a new drug treatment for ischaemic stroke patients have been published today in the journal ‘Lancet Neurology’.
Pilot trial of devices to extract clot from occluded arteries (PISTE)